Site search
Bibliography
Emerging pharmacotherapies for smoking cessation
Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA. cgarwood@wayne.edu
PURPOSE: The neurobiology of tobacco dependence and the efficacy and...
Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity
Laboratory of Physiological Studies, NIH/NIAAA, Bethesda, Maryland 20892, USA.
OBJECTIVES: We aimed to explore the effects of pharmacologic inhibition of cannabinoid-1 (CB1) receptor in in vivo and in vitro models of doxorubicin...
Smoking cessation: lessons learned from clinical trial evidence
Minto Prevention and Rehabilitation Centre, University of Ottawa Heart Institute, Ottawa, Canada. breid@ottawaheart.ca
PURPOSE OF REVIEW: Cigarette smoking and exposure to secondhand smoke cause coronary heart disease. Cessation...
Significance of Cannabinoid CB(1) Receptors in Improgan Antinociception
Center for Neuropharmacology and Neuroscience, Albany Medical College, Albany, New York.
Improgan is a congener of the H(2) antagonist cimetidine, which produces potent antinociception. Because a) the mechanism of action of...
Grooming, scratching and feeding: role of response competition in acute anorectic response to rimonabant in male rats
Behavioural Neuroscience Laboratory, Institute of Psychological Sciences, University of Leeds, Leeds, LS2 9JT, UK, r.j.rodgers@leeds.ac.uk.
RATIONALE: Although the CB1 receptor antagonist/inverse agonist rimonabant acutely...
This section of the site is dedicated to published Rimonabant related scientific studies that discuss its use and effects.